晨光文具(603899.SH)業績快報:2021年度淨利潤升20.91%至15.18億元
格隆匯3月8日丨晨光文具(603899.SH)發佈2021年度業績快報,實現營業收入176.07億元,同比增長34.02%;利潤總額18.63億元,同比增長22.80%;歸屬於上市公司股東的淨利潤15.18億元,同比增長20.91%;基本每股收益1.64元。
營收增長主要是傳統核心業務繼續保持穩健增長,新業務辦公直銷晨光科力普和零售大店九木雜物社繼續保持高速增長。
2021年是公司新的五年戰略開局之年,公司用新發展理念提高發展質量和效益。報吿期內,公司穩定推進公司發展戰略和經營計劃落地,全面推進傳統核心業務穩定發展,持續發展壯大新業務,保持了健康有質量的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.